<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586247</url>
  </required_header>
  <id_info>
    <org_study_id>07/47</org_study_id>
    <nct_id>NCT01586247</nct_id>
  </id_info>
  <brief_title>The Effect of a Prebiotic, Probiotic and Synbiotic on the Gut Microbiota and Immune Response of Older Volunteers (GOS)</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized Crossover Study of a Prebiotic (Galacto-oligosaccharides, GOS), Probiotic (B.Lactis, BI07) and Synbiotic (GOS + BI07) on the Gut Microbiota and Immune Response of Older Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy older volunteers will be recruited to a study where they will be given four different
      treatments over a 28 week period. These treatments include: a prebiotic, a probiotic, a
      synbiotic (prebiotic + probiotic) and a placebo. Faecal samples, blood and saliva will be
      collected and analysed for changes in faecal microbial populations and selected immune
      responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the effect of GOS (administered at
      8g/day), B. lactis BI07 (administered at 109 CFU/day) and the synbiotic (8g/day of GOS and
      109 CFU/day of B. lactis BI07) on the human gut microbiota.

      A double-blind, placebo-controlled, randomized crossover study will be conducted in 40
      healthy older (≥60 years of age) volunteers. The placebo will consist of maltodextrin (a food
      grade ingredient, administered at 8g/day).

      Changes in the gut microbiota will be determined by measuring bacterial population levels in
      human faeces using 16S rRNA targeted oligonucleotide probes and fluorescence in situ
      hybridisation. Faecal pH will be measured and the production of short chain fatty acids
      (SCFA) will be analysed and quantified using high performance liquid chromatography (HPLC).

      The secondary objective of this study is to examine the effect on cellular immune function.
      This will be achieved by investigating phagocytosis activity, natural killer cells which are
      CD4+, CD8+, CD25+ and CD2+ and CD3+ subsets, the marker of T-cell maturation period.,
      salivary IgA levels, inflammatory markers (plasma - tumour necrosis factor (TNF), IL6, IL1,
      chemokines and soluble adhesion molecules).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes to the gut microbiota</measure>
    <time_frame>Baseline and after 21d treatment</time_frame>
    <description>The primary objective of this study is to determine the effect of GOS (administered at 8g/day), B. lactis BI07 (administered at 109 CFU/day) and the synbiotic (8g/day of GOS and 109 CFU/day of B. lactis BI07) on the human gut microbiota. Changes in the gut microbiota will be determined by measuring bacterial population levels in human faeces using 16S rRNA targeted oligonucleotide probes and fluorescence in situ hybridisation. Faecal pH will be measured and the production of short chain fatty acids (SCFA) will be analysed and quantified using high performance liquid chromatography (HPLC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune function</measure>
    <time_frame>Baseline and after 21d treatment</time_frame>
    <description>To examine the effect of GOS (administered at 8g/day), B. lactis BI07 (administered at 109 CFU/day) and the synbiotic (8g/day of GOS and 109 CFU/day of B. lactis BI07 ) on cellular immune function in 40 healthy older (≥60 years of age) volunteers. This will be achieved by investigating phagocytosis activity, natural killer cells which are CD4+, CD8+, CD25+ and CD2+ and CD3+ subsets, the marker of T-cell maturation period., salivary IgA levels, inflammatory markers (plasma - tumour necrosis factor (TNF), IL6, IL1, chemokines and soluble adhesion molecules).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gut Microbiota</condition>
  <condition>Immune Function</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8g/day maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8g/day galacto-oligosaccharides (GOS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>109 CFU/day B. lactis BI07</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>8g/day galacto-oligosaccharide + 10^9 CFU/day B.lactis</description>
    <arm_group_label>Synbiotic</arm_group_label>
    <other_name>GOS Bi-07</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>8g/day maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <description>8g/day galacto-oligosaccharide</description>
    <arm_group_label>Prebiotic</arm_group_label>
    <other_name>GOS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>10^9 CFU/day B.lactis</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Bi-07</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a signed consent form,

          -  age &gt;60 years

          -  good general health

          -  not in the residential care.

        Exclusion Criteria:

          -  evidence of physical or mental disease

          -  planned major surgery

          -  use of antibiotics within the previous six months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Rastall</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Reading</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Reading</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG6 6AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Caroline Childs</investigator_full_name>
    <investigator_title>Post doctoral research fellow</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

